louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05786378: Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
Official title: Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Hearing Loss, Sudden
Hearing Loss, Sensorineural
Hearing Loss
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-03-27
Enrollment: 23
Sex: ALL
Minimum age (years): 5
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Assessment of the efficacy of Intratympanic platelet rich plasma injection for treatment of idiopathic suden sensorineural hearing loss

Detailed description: Sensorineural hearing loss is the collective term for hearing damage to the cochlea and auditory nerve and is by far the most common type of hearing loss in adults, accounting for over 90% of all cases. Sensorineural hearing loss is a heterogeneous disorder, which can arise due to damage to pathway for sound impulses from the hair cells of inner ear to auditory nerve and less commonly brain.

Sensorineural hearing loss is a challenge to physicians, as it progresses with age and causes significant reductions in quality of life and there are no treatments to reverse its effects, other than sound amplification with the use of hearing aids or direct auditory nerve stimulation via cochlear implantation.

Platelet-rich Plasma (PRP) Therapy is a cutting-edge procedure that is revolutionizing the hearing loss and deafness. Intratympanic instillation of Platelet-rich Plasma (PRP) does wonder to the hair cells of inner ear, thus improving the hearing.

Eligibility criteria: Inclusion Criteria:

* Patients have sudden idiopathic sensorineural hearing loss

Exclusion Criteria:

1. patients has previous ear surgery.
2. patients has absent cochlea in CT or MRI
3. patients has Cancer,Chronic liver disease, Hemodynamic instability,Hypofibrinogenemia, Platelet dysfunction syndromes, Systemic disorder, sepsis, Low platelet count.

Primary outcomes:
measure: Changes in Pure Tone Averages
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Otorhinolaryngeology Departement, Faculty of Medicine , Assuit Univerisity
state: Assuit
Study officials:
References:
Clinical trial NCT05579678: APOLLO: Personalized rehAbilitation PrOgram in aLLOgeneic Bone Marrow Transplantation
Official title: APOLLO: Personalized rehAbilitation PrOgram in aLLOgeneic Bone Marrow Transplantation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Allogeneic Disease
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2022-10-14
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: individuals scheduled to undergo allogeneic transplantation

Brief summary: People who undergo allogeneic bone marrow transplant for blood cancers receive the highest chemotherapy doses possible that humans can receive and still survive. As a result, they have devastating side effects during the procedure and for many years afterwards. Damage to organs and muscles cause long-lasting physical weakness and the psychological experience is severe enough to be termed 'post traumatic stress disorder' that also lasts for many years. These effects are worsened by the fact that most Canadians live several hours away from treatment and transplant centers, leaving them entirely on their own to manage these difficult long term effects. The APOLLO team will perform a qualitative study to learn the experiences of people undergoing allogeneic bone marrow transplant while they receive access to a supportive care computer 'app' and telephone support from nursing, exercise and nutrition experts. In this way, the APOLLO team will learn the most helpful type and timing of supportive care from those who know best.


Eligibility criteria: Inclusion Criteria:

* eligible for allogeneic transplantation

Exclusion Criteria:

* none

Primary outcomes:
measure: Title: Acceptability of a multimodal supportive care
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
Study officials:
References:
Clinical trial NCT05578378: Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL
Official title: Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in Refractory/Relapsed Acute Lymphoblastic Leukemia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Acute Lymphoblastic Leukemia
Lead sponsor: The First Affiliated Hospital of Soochow University
Sponsor class: OTHER
Collaborators: name: The First People's Hospital of Changzhou
name: Zhongda Hospital
name: Suzhou Municipal Hospital
First posted: 2022-10-13
Enrollment: 32
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To explore the efficiency and safety of CLAG regimen in R/R ALL

Detailed description: R/R Acute Lymphoblastic Leukemia has poor response to second-line chemotherapy.Here,we want to explore efficiency and safety of CLAG regimen in R/R ALL.

Eligibility criteria: Inclusion Criteria:

The patients meet the diagnostic criteria for Relapsed/Refractroy B-ALL. ECOG score is 0-3. Expecting life span is more than 6 weeks.

Exclusion Criteria:

Patients are combined with severe organ dysfunction or organ failure: Cardiac failure, Liver and kidney insufficiency.

Patients are combined with severe infection or other complications that can not tolerate chemotherapy.

Patients are considered as other tumor progression. Patients have used cladribine. Pregnant and lactating women will not be included.

Primary outcomes:
measure: CR (complete remission rate)
timeFrame: the first cycle (4 weeks)
Secondary outcomes:
measure: Overall survival(OS)
timeFrame: From the 1st day to the 365th day after enrollment.
measure: Progression-Free Survival （PFS）
timeFrame: From the 1st day to the 365th day after enrollment.
Other outcomes:
Locations:
city: Suzhou
country: China
facility: The First Affiliated Hospital of Soochow University
state: Jiangsu
Study officials:
affiliation: Study Principle investigator
name: Yue Han, MD/PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012 Sep 6;120(10):2032-41. doi: 10.1182/blood-2011-12-399287. Epub 2012 Apr 4.
Clinical trial NCT06650878: Desarda Tissue Technique Vs Lichtenstein Technique for Primary Inguinal Hernia Repair
Official title: Randomized Controlled Trial Comparing the Desarda Tissue Technique with the Lichtenstein Technique in Primary Inguinal Hernia Repair
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Inguinal Hernia Unilateral
Complications of Surgical Procedures or Medical Care
Keywords: Inguinal Hernia
lichtenstein technique
desarda technique
Lead sponsor: Consorci Sanitari de l'Alt Penedès i Garraf
Sponsor class: OTHER
First posted: 2024-10-21
Enrollment: 478
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate whether a surgical technique (Desarda) is superior to the commonly used surgical technique (Lichtenstein) in inguinal hernia repair concerning the occurrence of postoperative complications. The Lichtenstein technique involves the use of a mesh, while the Desarda technique does not.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with primary inguinal hernia.
* Body mass index below 31
* Indication for inguinal hernia repair via anterior approach, either as outpatient surgery (CMA) or elective admission.
* Legal capacity to provide informed consent.

Exclusion Criteria:

* Patients with a weak, thin, or divided external oblique aponeurosis.
* Participants diagnosed with any of the following conditions:

  * Ongoing oncological disease
  * Cirrhotic patients classified as Child B or higher
* Women who have previously undergone a cesarean section
* Cognitive or affective conditions that limit the ability to cooperate with the study procedures

Primary outcomes:
measure: Rate of Participants with Post-surgery Complications
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sant Pere de Ribes
country: Spain
facility: CSAPG
state: Barcelona
Study officials:
affiliation: CSAPG
name: Javier Errando, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01575678: The Effect of Melatonin on Nocturnal Enuresis
Official title: The Effect of Melatonin on Nocturnal Enuresis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Nocturnal Enuresis
Keywords: enuresis
melatonin
circadian rhythm
children
blood pressure
urine production
activity
sleep
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2012-04-11
Enrollment: 40
Sex: ALL
Minimum age (years): 6
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Aim: To investigate the effect of melatonin in bedwetting.

Detailed description: Design: Double blind randomized placebocontrolled trial using crossover.

Eligibility criteria: Inclusion Criteria:

* Monosymptomatic nocturnal enuresis
* Age 6-14 years
* Clinical examination normal
* ≥ 3 wet nights / week due to either nocturnal polyuria with normal bladder size or reduced functional bladder capacity with normal urine output

Exclusion Criteria:

* Constipation (by ROME III criteria)
* Day incontinence
* Overactive bladder (ICCS 2008 classification of symptoms)
* Current or past history of clinical or laboratory findings that can be related to diseases or - conditions (eg pregnancy) likely to change the parameters examined, especially diseases of the kidney and urinary tract, liver or endocrine disorder.
* Clinical signs of urinary tract infection
* Hypertension, blood pressure assessed by ambulatory measurement with blood pressure cuff
* Set treatment with one or more drugs

Primary outcomes:
measure: number of incontinence episodes
timeFrame: 10 weeks
Secondary outcomes:
measure: nocturnal blood pressure
timeFrame: 4 weeks
measure: activity level
timeFrame: 4 weeks
measure: bladder capacity
timeFrame: 4 weeks
measure: nocturnal urine production
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Center of Child Incontinence, Pediatric department, Aarhus Universityhospital
state: Region Midtjylland
Study officials:
affiliation: Pediatric department, Aarhus Universityhospital, Denmark
name: Søren Rittig, MD, dr.med
role: PRINCIPAL_INVESTIGATOR
References:
citation: Caldwell PH, Codarini M, Stewart F, Hahn D, Sureshkumar P. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev. 2020 May 4;5(5):CD002911. doi: 10.1002/14651858.CD002911.pub3.
Clinical trial NCT00180778: Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
Official title: Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Antiphospholipid Syndrome
Lead sponsor: Imperial College London
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 0
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Does the addition of steroids during the first trimester to the standard aspirin + heparin treatment reduce the miscarriage rates in women with antiphospholipid antibodies and recurrent first trimester miscarriage in those who had an unsuccessful pregnancy with aspirin + heparin?

Detailed description: Over the last decade, the APS has emerged as most important treatable cause of recurrent miscarriages. The pathogenesis of fetal loss in this condition is still remains obscure. Despite the success of aspirin + heparin treatment, some pregnant women with APS repeatedly miscarry even on treatment. The trial is designed to determine if addition of steroids has an success in these women. This is in view of recent in vitro data from our unit reporting that there is an increase decidual cytokine response in APS positive women.

Eligibility criteria: Inclusion Criteria:

History of 3 or more consecutive miscarriages and positive antiphospholipid antibodies on at least two occasions more than 6 weeks apart before becoming pregnant and an unsuccessful pregnancy with aspirin + heparin with a karyotype of miscarriage either unavailable or normal (46XX/ 46XY).

Exclusion Criteria:

Abnormal karyotype of women or partner, previous thromboembolism, SLE, diabetes mellitus, hypertension, sensitivity to aspirin, heparin and prednisolone, multiple pregnancy.

Primary outcomes:
measure: Successful pregnancy outcome
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: St. Mary's Hospital
Study officials:
affiliation: Imperial College London
name: Raj Rai, MRCOG
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hamulyak EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/14651858.CD012852.pub2.
Clinical trial NCT03699878: Impact of Perioperative Shedding of the Endothelial Glycocalyx on Short-term Postoperative Complication in Patients Undergoing Robot-assisted Esophagectomy
Official title: Impact of Perioperative Shedding of the Endothelial Glycocalyx on Short-term Postoperative Complication in Patients Undergoing Robot-assisted Esophagectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Robotic Esophagectomy
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2018-10-09
Enrollment: 221
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients 20 years or older who undergo robotic esophagectomy

Brief summary: The aim of this study was to determine whether changes in serum levels of syndecan-1 before and after surgery, which is an index related to injury of the endothelial glycocalyx layer, are associated with postoperative short-term complications and mortality in patients undergoing robotic esophagectomy.


Eligibility criteria: Inclusion Criteria:

1. patients 20 years or older who undergo robotic esophagectomy

Exclusion Criteria:

1. Emergency surgery
2. If the subject includes a person who can not read the written consent (eg, illiterate, foreigner, etc.)
3. Chronic kidney disease (eGFR \<30 mL / min / 1.73 m2)
4. Pregnant and lactating women
5. Use of oral anticoagulants

Primary outcomes:
measure: base blood concentration of syndecan-1
timeFrame: within 1 hour before surgery
measure: blood concentration of syndecan-1 at the end of the surgery
timeFrame: within 5 minutes after the end of surgery (when thd surgical drape is removed)
measure: blood concentration of syndecan-1 at 24 hours after surgery
timeFrame: 24 hours after the end of surgery
Secondary outcomes:
measure: Unanticipated Post-Operative Invasive Procedure (STS GTSD 2.41 #3330)
timeFrame: during this 1 day hospital visit.
measure: Anastomotic leak following esophageal surgery(STS GTSD 2.41 #3350)
timeFrame: within 30days after end of surgery
measure: Respiratory Failure(STS GTSD 2.41 #3480)
timeFrame: within 30days after end of surgery
measure: initial ventilatory support greater than 48 hours (STS GTSD 2.41 #3520)
timeFrame: within 30days after end of surgery
measure: pneumonia (STS GTSD 2.41 #3460)
timeFrame: within 30days after end of surgery
measure: renal failure(STS GTSD 2.41 #3810)
timeFrame: within 30days after end of surgery
measure: mortality(Status 30 Days after Surgery, STS GTSD 2.41 #3950)
timeFrame: 30days post-surgery
measure: Acute kidney injury
timeFrame: within 48 h after end of surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine
Study officials:
References:
Clinical trial NCT06007378: Optimizing Postoperative Pain Control After Laparoscopic Colorectal Surgery
Official title: Optimizing Postoperative Pain Control After Laparoscopic Colorectal Surgery by Supplementing Ultrasound-guided Erector Spinae Plane Block With Ketamine or Transdermal Fentanyl Patch
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2023-08-23
Enrollment: 120
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Erector spinae plane block (ESPB) is a novel regional block technique that was proven to have superior outcomes in relieving postoperative pain in colorectal surgeries.Ketamine enhances the impact of local anaesthetics by reducing the duration and extent of motor block while shortening the onset of sensory and motor block.Transdermal Fentanyl Patch (TFP) was better than transdermal buprenorphine in postoperative analgesia following abdominal surgeries.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing laparoscopic colorectal surgery.
* American Society of Anesthesiologists (ASA) physical status I or II.

Exclusion Criteria:

* Known allergy to one of the study medications.
* Skin infections at the site of the needle puncture.
* Hepatic, renal or cardiac dysfunction.
* Patients diagnosed with obstructive sleep apnoea

Primary outcomes:
measure: The total rescue analgesia consumption (mg)
timeFrame: in the first 48 hours after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain-Shams University Hospitals
Study officials:
References:
Clinical trial NCT00618878: Electroacupuncture and Laser Therapy on Neck Pain
Official title: The Effects of Electroacupuncture and Laser Therapy on Chronic Neck Pain, A Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Neck Pain
Lead sponsor: Logan College of Chiropractic
Sponsor class: OTHER
First posted: 2008-02-20
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study examines the use of electroacupuncture and laser therapy to treat chronic neck pain.


Eligibility criteria: Inclusion Criteria:

* people with chronic neck pain, participants with a VAS level between 3 and 10 will be included in the study

Exclusion Criteria:

* history of cancer, tuberculosis, pacemaker usage, pregnancy, hemophilia, cardiovascular disease, osteoporosis

Primary outcomes:
measure: Neck Pain Disability Index Questionnaire, Neck Bournemouth Questionnaire, Revised Oswestry Pain Questionnaire
timeFrame: within 30 days of the last treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Chesterfield
country: United States
facility: Logan College of Chiropractc
state: Missouri
Study officials:
affiliation: Logan College of Chiropractic
name: John Zhang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01661478: Healthcare Provider Attitudes Towards Patients With Substance Use Before and After Implementation of the SBIRT Model in the Emergency Room
Official title: Healthcare Provider Attitudes Towards Patients With Substance Use Before and After Implementation of the SBIRT Model in the Emergency Room
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patients With Substance Abuse
Healthcare Provider Attitudes
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2012-08-09
Enrollment: 200
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Personnel in the Emergency Medicine Department and the Department of Psychiatry

Brief summary: The purpose of this quality improvement research project is to briefly survey attitudes among healthcare providers toward patients with substance use disorders before and after substance abuse counselors are placed in the Emergency Room.

Detailed description: The purpose of this quality improvement research project is to briefly survey attitudes among healthcare providers toward patients with substance use disorders before and after substance abuse counselors are placed in the Emergency Room. SBIRT stands for Screening Brief Intervention and Referral to Treatment. The pre-test survey contains 10 questions about attitudes toward patients with substance use disorders and the post-test survey consists of 13 questions about attitudes toward patients with substance use disorders and questions regarding the SBIRT model itself. Health care providers will be surveyed before the SBIRT Counselors begin and again at 6 months, after full SBIRT program with substance counselors on site has been in place, as a part of their regular staff education requirements. Part of the goal of the SBIRT counselors is to educate providers about treatment and analyze data collected by and comments of Emergency Room staff.

Eligibility criteria: Inclusion Criteria:

* UAB Emergency Department Staff (attending, resident, nurse, social worker, case manager, patient care technician) or Psychiatry Emergency Services staff (nurses, social workers and residents)

Exclusion Criteria:

* Not employed in UAB Emergency Department

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
city: Birmingham
country: United States
facility: University of Alabama Birmingham
state: Alabama
Study officials:
References: